Nu.Q®
Discover the risk for certain canine cancers in-house, instantly.
Now Available! Nu.Q® on the Element i+TM analyser is exclusively available from Heska as an
in-house test option.
-
Innovative Cancer Assessment
Measures canine plasma nucleosome concentration and helps determine current likelihood of certain cancers.
-
Affordable Testing & Immediate Results
Refine your differential list in minutes, helping you inform pet owners of risk level for certain common cancer types.
-
Accurate & Convenient
Only requires 50μL of EDTA plasma from a patient with high (>70%) detection rates for lymphoma and hemangiosarcoma - all at an affordable cost for pet owners.
-
Exclusively In-House with Heska
Evaluate risk of certain cancer types instantly. Simply run a Nu.Q® blood test on the in-house Element i+ analyser.
-
Seamless Integration
The efficient workflow for Nu.Q® on the Element i+ Analyser makes it easy to add to routine wellness diagnostics for your patients that are at high risk for cancer.
-
Cutting Edge
Element i+ delivers fast and accurate immunodiagnostic test results on a sleek and compact platform with an expanding test menu.
Stop overpaying for in-clinic blood testing and analysis.
Heska’s Reset program provides veterinarians with accurate, better and faster blood testing and analysis at 35% less cost than with other competitive in-house diagnostic laboratory services.
Nu.Q® on the Element i+ is the industry's only canine cancer blood test, offered exclusively by Heska.
Evaluate risk of certain cancer types instantly.
Innovative
Measures canine plasma nucleosome concentration and helps determine current likelihood of certain cancers.
Accurate, Fast and In-House
Get quantitative results and develop a plan of action before your patient goes home.
Convenient
Requiring only 50 uL of EDTA plasma from your patient.
We've switched over 3 of our practices to Heska and it was a great move for our hospitals and our teams. We rarely have any issues with the equipment and the support provided has been excellent both over the phone and in person. I would have no hesitation in recommending the Heska team and the analysers that they provide. It has been a great business decision.
Vet Ventures
Technical Details & Downloads
Empowering veterinary care teams with the industry’s only in-house canine cancer blood test.
1 in 4 dogs get cancer.1 Cancer is a leading cause of death in older dogs, with nearly 50% over 10 years of age developing the disease1. Over 6 million dogs are diagnosed2 with cancer in the United States every year — often far too late. With Nu.Q®, you can help determine the current likelihood of certain cancers — like lymphoma and hemangiosarcoma. Nu.Q® on the Element i+ allows you to interpret results and develop a plan of action before your patient goes home.
Indications:
- Older dogs (≥ 7 years of age)
- Younger dog breeds (≥ 4 years of age) known to be at a higher risk of developing cancer
You can evaluate risk of certain cancer types instantly. Simply run a Nu.Q® blood test on the in-house Element i+ analyser — both cost-effective and simple, requiring only 50μL of EDTA plasma from your patient. Nu.Q® is an accessible, affordable, and quantitative blood test for nucleosomes in dogs.
The Element i+ Immunodiagnostic Analyser supports your diagnostic needs with the following tests:
Canine Cancer | T4 | cTSH | Cortisol | Progesterone | cCRP
All on a sleek and compact platform offering…
- Accurate and fast quantitative results
- Touch screen for easy operation
- Room temperature storage of test cartridges
- Bi-directional interface simplifies patient data entry with PMS integration
REFERENCES:
1. Cancer in Pets. American Veterinary Medical Association. (2022). Retrieved 9 July 2022, from https://www.avma.org/resources/pet-owners/petcare/cancer-pets
2. National Cancer Institute: https://ccr.cancer.gov/comparative-oncology-program/about
3. Wilson-Robles, H., Bygott, T., Kelly, T., Miller, T., Miller, P., & Matsushita, M. et al. (2022). Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Veterinary Research, 18(1). https://doi.org/10.1186/s12917-022-03429-8
PEER-REVIEWED STUDIES
Lymphoma paper: https://pubmed.ncbi.nlm.nih.gov/34399763/
Hemangiosarcoma paper: https://pubmed.ncbi.nlm.nih.gov/34187493/
2020 cancer vs healthy dogs: https://pubmed.ncbi.nlm.nih.gov/32866177/
*Nu.Q® ️is not a confirmatory test for cancer. Nu.Q®️ results should act as an impetus to perform additional diagnostics to obtain a diagnosis. Elevated plasma nucleosome concentration does not tell you which cancer is present, and further diagnostics will be needed. Certain inflammatory conditions may increase plasma nucleosome concentration and in these instances Nu.Q® cannot differentiate between cancer and an inflammatory response.
Nu.Q® is a registered trademark of VolitionRx Limited and its subsidiaries. The Nu.Q® Canine Cancer Test is supplied to Antech’s Heska affiliate under license by Belgian Volition SRL.
The Element i+ analyzer uses cutting-edge immunodiagnostics technology.
How does Nu.Q® work?
- DNA is compacted within a cell’s nucleus in the form of chromosomes.
- Nucleosomes (small structural units comprised of DNA and a histone protein core) allow chromosomes to stack and fold into their normal conformation within each cell nucleus.
- For certain types of cancer, nucleosomes are released into the blood and can be measured using specific antibodies.
- Nucleosomes in patient plasma measured with Nu.Q® can serve as a biomarker to help identify patients who may have cancer.3
REFERENCES:
1. Cancer in Pets. American Veterinary Medical Association. (2022). Retrieved 9 July 2022, from https://www.avma.org/resources/pet-owners/petcare/cancer-pets
2. National Cancer Institute: https://ccr.cancer.gov/comparative-oncology-program/about
3. Wilson-Robles, H., Bygott, T., Kelly, T., Miller, T., Miller, P., & Matsushita, M. et al. (2022). Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Veterinary Research, 18(1). https://doi.org/10.1186/s12917-022-03429-8
PEER-REVIEWED STUDIES
Lymphoma paper: https://pubmed.ncbi.nlm.nih.gov/34399763/
Hemangiosarcoma paper: https://pubmed.ncbi.nlm.nih.gov/34187493/
2020 cancer vs healthy dogs: https://pubmed.ncbi.nlm.nih.gov/32866177/
*Nu.Q® ️is not a confirmatory test for cancer. Nu.Q®️ results should act as an impetus to perform additional diagnostics to obtain a diagnosis. Elevated plasma nucleosome concentration does not tell you which cancer is present, and further diagnostics will be needed. Certain inflammatory conditions may increase plasma nucleosome concentration and in these instances Nu.Q® cannot differentiate between cancer and an inflammatory response.
Nu.Q® is a registered trademark of VolitionRx Limited and its subsidiaries. The Nu.Q® Canine Cancer Test is supplied to Antech’s Heska affiliate under license by Belgian Volition SRL.
Heska Support Teams are Here for You
We’re Available When You Need Us
Rest assured that when you need help, have questions, or have difficulties, we have you covered.
- Available 9:00am – 5:00pm AEST Daily
- Emergency Support During Off-Hours
